When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis

Norman J KachuckUniversity of Southern California, Keck School of Medicine, Los Angeles, CA, USAAbstract: New more powerful therapies for the treatment of multiple sclerosis may also confer a potential for unprecedented life-endangering side effects. How does a physician respond to a patient&amp...

Full description

Bibliographic Details
Main Author: Kachuck NJ
Format: Article
Language:English
Published: Dove Medical Press 2011-04-01
Series:Neuropsychiatric Disease and Treatment
Online Access:http://www.dovepress.com/when-neurologist-and-patient-disagree-on-reasonable-risk-new-challenge-a7145
id doaj-be798b95f75e4e0ba2267b0d1476072e
record_format Article
spelling doaj-be798b95f75e4e0ba2267b0d1476072e2020-11-25T00:10:59ZengDove Medical PressNeuropsychiatric Disease and Treatment1176-63281178-20212011-04-012011Issue 1197208When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosisKachuck NJNorman J KachuckUniversity of Southern California, Keck School of Medicine, Los Angeles, CA, USAAbstract: New more powerful therapies for the treatment of multiple sclerosis may also confer a potential for unprecedented life-endangering side effects. How does a physician respond to a patient's request for a treatment the benefit of which cannot be clearly established as worth its risk? The current challenge with prescription of natalizumab (Tysabri®, Biogen Idec) is used to illustrate how this conflict creates an opportunity to re-examine our goals as physicians and the nature of the physician-patient relationship. Understanding the physician's role in that partnership, and the ethical and psychological issues impacting on how reasonable risk is determined, can improve the neurologist's capacity to explicate such quandaries. Redefining what is required to mediate disagreement between doctors and patients about reasonable risk is at the heart of why many of us became physicians. However, such nuanced interpersonal dynamics of patient care can be neglected due to the time and resource pressures of our practices. These demands have increased the seductiveness of the efficiencies promoted by the trend toward the pseudoobjectification of evidence-based care, which has arguably monopolized the healing conversation often to the detriment of the shared narrative. We examine and attempt to reframe the fiduciary and biopsychosocial contretemps of the doctor and patient disagreeing on risk, emphasizing its humanistic, relational dimensions.Keywords: multiple sclerosis, natalizumab, medical ethics, medical decision-making, patient-physician relationship http://www.dovepress.com/when-neurologist-and-patient-disagree-on-reasonable-risk-new-challenge-a7145
collection DOAJ
language English
format Article
sources DOAJ
author Kachuck NJ
spellingShingle Kachuck NJ
When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis
Neuropsychiatric Disease and Treatment
author_facet Kachuck NJ
author_sort Kachuck NJ
title When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis
title_short When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis
title_full When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis
title_fullStr When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis
title_full_unstemmed When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis
title_sort when neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis
publisher Dove Medical Press
series Neuropsychiatric Disease and Treatment
issn 1176-6328
1178-2021
publishDate 2011-04-01
description Norman J KachuckUniversity of Southern California, Keck School of Medicine, Los Angeles, CA, USAAbstract: New more powerful therapies for the treatment of multiple sclerosis may also confer a potential for unprecedented life-endangering side effects. How does a physician respond to a patient's request for a treatment the benefit of which cannot be clearly established as worth its risk? The current challenge with prescription of natalizumab (Tysabri®, Biogen Idec) is used to illustrate how this conflict creates an opportunity to re-examine our goals as physicians and the nature of the physician-patient relationship. Understanding the physician's role in that partnership, and the ethical and psychological issues impacting on how reasonable risk is determined, can improve the neurologist's capacity to explicate such quandaries. Redefining what is required to mediate disagreement between doctors and patients about reasonable risk is at the heart of why many of us became physicians. However, such nuanced interpersonal dynamics of patient care can be neglected due to the time and resource pressures of our practices. These demands have increased the seductiveness of the efficiencies promoted by the trend toward the pseudoobjectification of evidence-based care, which has arguably monopolized the healing conversation often to the detriment of the shared narrative. We examine and attempt to reframe the fiduciary and biopsychosocial contretemps of the doctor and patient disagreeing on risk, emphasizing its humanistic, relational dimensions.Keywords: multiple sclerosis, natalizumab, medical ethics, medical decision-making, patient-physician relationship
url http://www.dovepress.com/when-neurologist-and-patient-disagree-on-reasonable-risk-new-challenge-a7145
work_keys_str_mv AT kachucknj whenneurologistandpatientdisagreeonreasonablerisknewchallengesinprescribingforpatientswithmultiplesclerosis
_version_ 1725405837779795968